BeiGene, Ltd. (NASDAQ:BGNE) Short Interest Update

BeiGene, Ltd. (NASDAQ:BGNE) was the target of a significant increase in short interest in August. As of August 31st, there was short interest totalling 2,250,000 shares, an increase of 11.9% from the August 15th total of 2,010,000 shares. Based on an average daily volume of 271,300 shares, the short-interest ratio is presently 8.3 days.

BeiGene Stock Down 1.0 %

NASDAQ:BGNE traded down $2.04 during trading hours on Monday, reaching $196.45. The company’s stock had a trading volume of 200,577 shares, compared to its average volume of 249,254. The company has a market cap of $19.06 billion, a price-to-earnings ratio of -25.84 and a beta of 0.61. BeiGene has a one year low of $126.97 and a one year high of $215.00. The business’s 50-day moving average is $177.16 and its 200-day moving average is $163.29. The company has a debt-to-equity ratio of 0.06, a current ratio of 1.98 and a quick ratio of 1.75.

BeiGene (NASDAQ:BGNE) last released its earnings results on Wednesday, August 7th. The company reported ($1.15) earnings per share for the quarter, beating the consensus estimate of ($2.27) by $1.12. BeiGene had a negative net margin of 16.91% and a negative return on equity of 14.93%. The business had revenue of $929.20 million during the quarter, compared to analysts’ expectations of $810.34 million. During the same quarter last year, the company earned ($3.64) earnings per share. The firm’s revenue was up 56.1% on a year-over-year basis. Equities research analysts predict that BeiGene will post -5.13 EPS for the current year.

Wall Street Analyst Weigh In

Several research firms have recently commented on BGNE. JPMorgan Chase & Co. upped their target price on BeiGene from $194.00 to $200.00 and gave the company an “overweight” rating in a report on Tuesday, August 20th. Bank of America reduced their price objective on BeiGene from $180.00 to $152.50 and set a “neutral” rating for the company in a research report on Tuesday, July 9th. Finally, Citigroup boosted their price objective on BeiGene from $269.00 to $288.00 and gave the stock a “buy” rating in a research report on Thursday, August 8th. Three investment analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $233.42.

Insider Transactions at BeiGene

In other news, insider Titus B. Ball sold 137 shares of the business’s stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $189.94, for a total transaction of $26,021.78. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. In related news, COO Xiaobin Wu sold 5,556 shares of the company’s stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $189.65, for a total value of $1,053,695.40. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Titus B. Ball sold 137 shares of the company’s stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $189.94, for a total transaction of $26,021.78. The disclosure for this sale can be found here. Over the last three months, insiders have sold 13,210 shares of company stock valued at $2,269,721. Corporate insiders own 7.43% of the company’s stock.

Institutional Trading of BeiGene

Hedge funds have recently modified their holdings of the company. Headlands Technologies LLC bought a new position in BeiGene in the first quarter valued at approximately $50,000. Benjamin F. Edwards & Company Inc. raised its holdings in shares of BeiGene by 51.5% during the first quarter. Benjamin F. Edwards & Company Inc. now owns 821 shares of the company’s stock worth $128,000 after acquiring an additional 279 shares during the period. BI Asset Management Fondsmaeglerselskab A S acquired a new stake in shares of BeiGene during the fourth quarter worth $183,000. Acadian Asset Management LLC increased its stake in BeiGene by 204.1% in the 1st quarter. Acadian Asset Management LLC now owns 1,265 shares of the company’s stock valued at $197,000 after buying an additional 849 shares during the last quarter. Finally, Envestnet Portfolio Solutions Inc. acquired a new stake in BeiGene in the 1st quarter valued at $209,000. Institutional investors and hedge funds own 48.55% of the company’s stock.

BeiGene Company Profile

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC.